Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(rotigotine transdermal system)
175 results
  • Pain in Parkinson's disease: new concepts in pathogenesis and treatment. [Journal Article]
    Curr Opin Neurol 2019; 32(4):579-588Rukavina K, Leta V, … Ray Chaudhuri K
  • CONCLUSIONS: Pain in Parkinson's disease is not simply a consequence of motor complainants. The management of Parkinson's disease-related pain implicates maintenance of stable levels of dopaminergic drugs. Nondopaminergic pharmacological therapies (prolonged-release oxycodone/naloxone, duloxetine, BTX) and nonpharmacological interventions (DBS, physiotherapie) may also be beneficial in treatment of Parkinson's disease pain.
  • Rotigotine Transdermal Patch: A Review in Parkinson's Disease. [Journal Article]
    CNS Drugs 2019; 33(7):707-718Frampton JE
  • Rotigotine (Neupro®), a non-ergolinic dopamine agonist (DA), is administered once daily via a transdermal patch (TP) that delivers the drug over a 24-h period. In the EU, the rotigotine TP is approved as monotherapy for the treatment of early Parkinson's disease (PD) and as combination therapy with levodopa throughout the course of the disease. It is also approved for the treatment of PD in numer…
  • Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson's Disease. [Journal Article]
    J Parkinsons Dis 2018; 8(s1):S65-S72van Wamelen DJ, Grigoriou S, … Odin P
  • Continuous dopaminergic stimulation in Parkinson's disease (PD) has several advantages over pulsatile, non-continuous, stimulation. These therapies currently consist of pump-based and transcutaneous therapies and are based on a more constant delivery of the dopaminergic drug resulting in continuous dopaminergic stimulation and a more stable treatment effect. Several clinical and experimental obse…
  • Available and future treatments for atypical parkinsonism. A systematic review. [Review]
    CNS Neurosci Ther 2019; 25(2):159-174Moretti DV
  • CONCLUSIONS: Transdermal rotigotine, autologous mesenchymal stem cells, tideglusib, and coenzyme Q10 along with donepezil, rivastigmine, memantine, and the deep brain stimulation have shown some benefits in alleviating symptoms in APS. Moreover, many new clinical trials are ongoing testing microtubule stabilizer, antitau monoclonal antibody, tau acetylation inhibition, cell replacement, selective serotonin reuptake inhibitor, active immunization, inhibition of toxic α-synuclein oligomers formation, and inhibition of microglia.A detailed knowledge of the pathological mechanism underlying the disorders is needed, and disease-modifying therapies are required to offer better therapeutic options to physician and caregivers of APS patients.
New Search Next